[HIGHLIGHTS] New Therapeutic Option Prevents Relapses in Women with Most Common Breast Cancer

First therapeutic novelty in 20 years as an additional treatment for a type of breast cancer. HR-positive and HER2-negative luminal breast cancer is the most common subtype and accounts for nearly 70% of all breast tumor cases.

One in eight Spanish women will have breast cancer at some point in their lives, according to the Spanish Society of Medical Oncology (SEOM) In Spain, 761 patients (out of a total of 5,101) from 40 centres have already benefited from this new therapeutic combination.